Is More Better with Radium-223 for Metastatic Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-056)
Released Monday, 20th August 2018
Good episode? Give it some love!
Is More Better with Radium-223 for Metastatic Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-056)
Is More Better with Radium-223 for Metastatic Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-056)
Monday, 20th August 2018
Good episode? Give it some love!
Rate Episode
Dr. Daniel Goldstein reviews data in genitourinary oncology from ASCO 2018, including a study of higher dose or prolonged duration of radium-223 (Xofigo) compared to standard dosing for 6 months with this agent in patients with metastatic prostate cancer.
Show More
Rate
Join Podchaser to...
- Rate podcasts and episodes
- Follow podcasts and creators
- Create podcast and episode lists
- & much more
Episode Tags
Do you host or manage this podcast?
Claim and edit this page to your liking.
,Claim and edit this page to your liking.
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us